Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 6, 2011, Pages 1144-1152

  Kuznetsov, Andrey V ^a   Margreiter, Raimund ^a   Amberger, Albert ^a   Saks, Valdur ^b   Grimm, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Domaine Universitaire   (France)

Author keywords

Confocal imaging; Doxorubicin; Mitochondria; Mitochondrial function; Reactive oxygen species, ROS; Redox state

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; DOXORUBICIN; FLAVOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DEPOLARIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CALCIUM; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CELL CYCLE; CELL LINE, TUMOR; CELL RESPIRATION; CELL SURVIVAL; CITRATE (SI)-SYNTHASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ELECTRON TRANSPORT COMPLEX I; HT29 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MITOCHONDRIA; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; TIME FACTORS; UNCOUPLING AGENTS;

EID: 79955661144     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.03.002     Document Type: Article

References (69)

1. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6:513-519.
2. Newmeyer D.D., Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003, 112:873.
3. Alirol E., Martinou J.C. Mitochondria and cancer: is there a morphological connection?. Oncogene 2006, 25:4706-4716.
4. Carew J.S., Huang P. Mitochondrial defects in cancer. Mol. Cancer 2002, 1:9.
5. Mayevsky A. Mitochondrial function and energy metabolism in cancer cells: past overview and future perspectives. Mitochondrion 2009, 9:165-179.
6. Harper M.E., Antoniou A., Villalobos-Menuey E., Russo A., Trauger R., Vendemelio M., George A., Bartholomew R., Carlo D., Shaikh A., Kupperman J., Newell E.W., Bespalov I.A., Wallace S.S., Liu Y., Rogers J.R., Gibbs G.L., Leahy J.L., Camley R.E., Melamede R., Newell M.K. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 2002, 16:1550-1557.
7. Arcamone F., Animati F., Capranico G., Lombardi P., Pratesi G., Manzini S., Supino R., Zunino F. New developments in antitumor anthracyclines. Pharmacol. Ther. 1997, 76:117-124.
8. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54:1-7.
9. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
10. Gille L., Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 1997, 23:775-782.
11. Mott M.G. Anthracycline cardiotoxicity and its prevention. Ann. N. Y. Acad. Sci. 1997, 824:221-228.
12. Rajagopalan S., Politi P.M., Sinha B.K., Myers C.E. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988, 48:4766-4769.
13. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 1996, 125:47-58.
14. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339:900-905.
15. Childs A.C., Phaneuf S.L., Dirks A.J., Phillips T., Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002, 62:4592-4598.
16. Clementi M.E., Giardina B., Di S.E., Mordente A., Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003, 23:2445-2450.
17. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 1986, 261:3060-3067.
18. Demant E.J. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem. Pharmacol. 1991, 41:543-552.
19. Goormaghtigh E., Brasseur R., Ruysschaert J.M. Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem. Biophys. Res. Commun. 1982, 104:314-320.
20. Nicolay K., De K.B. Effects of adriamycin on respiratory chain activities in mitochondria from rat liver, rat heart and bovine heart. Evidence for a preferential inhibition of complex III and IV. Biochim. Biophys. Acta 1987, 892:320-330.
21. Papadopoulou L.C., Theophilidis G., Thomopoulos G.N., Tsiftsoglou A.S. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem. Pharmacol. 1999, 57:481-489.
22. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 1986, 261:3068-3074.
23. Mukhopadhyay P., Rajesh M., Batkai S., Kashiwaya Y., Hasko G., Liaudet L., Szabo C., Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1466-H1483.
24. Chandran K., Aggarwal D., Migrino R.Q., Joseph J., McAllister D., Konorev E.A., Antholine W.E., Zielonka J., Srinivasan S., Avadhani N.G., Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys. J. 2009, 96:1388-1398.
25. Balli E., Mete U.O., Tuli A., Tap O., Kaya M. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol. Histopathol. 2004, 19:1101-1108.
26. Tokarska-Schlattner M., Zaugg M., Da S.R., Lucchinetti E., Schaub M.C., Wallimann T., Schlattner U. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H37-H47.
27. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell. Cardiol. 2006, 41:389-405.
28. Friesen C., Fulda S., Debatin K.M. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ. 1999, 6:471-480.
29. Jiang Y.J., Sun Q., Fang X.S., Wang X. Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin. Mol. Med. 2009, 15:173-182.
30. Mhawi A.A. Interaction of doxorubicin with the subcellular structures of the sensitive and Bcl-xL-overexpressing MCF-7 cell line: confocal and low-energy-loss transmission electron microscopy. Micron 2009, 40:702-712.
31. Kuznetsov A.V., Strobl D., Ruttmann E., Konigsrainer A., Margreiter R., Gnaiger E. Evaluation of mitochondrial respiratory function in small biopsies of liver. Anal. Biochem. 2002, 305:186-194.
32. Kuznetsov A.V., Schneeberger S., Seiler R., Brandacher G., Mark W., Steurer W., Saks V., Usson Y., Margreiter R., Gnaiger E. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1633-H1641.
33. Kuznetsov A.V., Veksler V., Gellerich F.N., Saks V., Margreiter R., Kunz W.S. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat. Protoc. 2008, 3:965-976.
34. Kuznetsov A.V., Smigelskaite J., Doblander C., Janakiraman M., Hermann M., Wurm M., Scheidl S.F., Sucher R., Deutschmann A., Troppmair J. Survival signaling by C-RAF: mitochondrial reactive oxygen species and Ca2+ are critical targets. Mol. Cell. Biol. 2008, 28:2304-2313.
35. Andrienko T., Kuznetsov A.V., Kaambre T., Usson Y., Orosco A., Appaix F., Tiivel T., Sikk P., Vendelin M., Margreiter R., Saks V.A. Metabolic consequences of functional complexes of mitochondria, myofibrils and sarcoplasmic reticulum in muscle cells. J. Exp. Biol. 2003, 206:2059-2072.
36. Appaix F., Kuznetsov A.V., Usson Y., Kay L., Andrienko T., Olivares J., Kaambre T., Sikk P., Margreiter R., Saks V. Possible role of cytoskeleton in intracellular arrangement and regulation of mitochondria. Exp. Physiol. 2003, 88:175-190.
37. Huang S., Heikal A.A., Webb W.W. Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein. Biophys. J. 2002, 82:2811-2825.
38. Kuznetsov A.V., Mayboroda O., Kunz D., Winkler K., Schubert W., Kunz W.S. Functional imaging of mitochondria in saponin-permeabilized mice muscle, fibers. J. Cell Biol. 1998, 140:1091-1099.
39. Kim H.S., Lee Y.S., Kim D.K. Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology 2009, 84:300-309.
40. Premrov M.G., Zenobi R., Conforti A., Giganti M.G., Sinibaldi-Vallebona P. Modifications in morphology and size distribution induced by adriamycin in cultured leukemia cells. J. Chemother. 1989, 1:1154-1156.
41. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am. J. Physiol. 1996, 271:H2079-H2085.
42. Mizutani H., Tada-Oikawa S., Hiraku Y., Kojima M., Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005, 76:1439-1453.
43. Mayevsky A., Rogatsky G.G. Mitochondrial function in vivo evaluated by NADH fluorescence: from animal models to human studies. Am. J. Physiol. Cell Physiol. 2007, 292:C615-C640.
44. Mayevsky A., Barbiro-Michaely E. Use of NADH fluorescence to determine mitochondrial function in vivo. Int. J. Biochem. Cell Biol. 2009, 41:1977-1988.
45. Yang H., Yang T., Baur J.A., Perez E., Matsui T., Carmona J.J., Lamming D.W., Souza-Pinto N.C., Bohr V.A., Rosenzweig A., De C.R., Sauve A.A., Sinclair D.A. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007, 130:1095-1107.
46. Kunz W.S., Kuznetsov A.V., Winkler K., Gellerich F.N., Neuhof S., Neumann H.W. Measurement of fluorescence changes of NAD(P)H and of fluorescent flavoproteins in saponin-skinned human skeletal muscle fibers. Anal. Biochem. 1994, 216:322-327.
47. Kunz W.S., Winkler K., Kuznetsov A.V., Lins H., Kirches E., Wallesch C.W. Detection of mitochondrial defects by laser fluorimetry. Mol. Cell. Biochem. 1997, 174:97-100.
48. Kuznetsov A.V., Schneeberger S., Renz O., Meusburger H., Saks V., Usson Y., Margreiter R. Functional heterogeneity of mitochondria after cardiac cold ischemia and reperfusion revealed by confocal imaging. Transplantation 2004, 77:754-756.
49. Serafino A., Sinibaldi-Vallebona P., Lazzarino G., Tavazzi B., Di P.D., Rasi G., Ravagnan G. Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis. Anticancer Res. 2000, 20:3383-3394.
50. De O.F., Chauvin C., Ronot X., Mousseau M., Leverve X., Fontaine E. Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells. Oncogene 2006, 25:2646-2655.
51. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
52. Chacon E., Acosta D. Mitochondrial regulation of superoxide by Ca2+: an alternate mechanism for the cardiotoxicity of doxorubicin. Toxicol. Appl. Pharmacol. 1991, 107:117-128.
53. Chacon E., Ulrich R., Acosta D. A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes. Biochem. J. 1992, 281:871-878.
54. Solem L.E., Henry T.R., Wallace K.B. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 1994, 129:214-222.
55. Green P.S., Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta 2002, 1588:94-101.
56. Cheneval D., Muller M., Carafoli E. The mitochondrial phosphate carrier reconstituted in liposomes is inhibited by doxorubicin. FEBS Lett. 1983, 159:123-126.
57. Muller M., Cheneval D., Carafoli E. Doxorubicin inhibits the phosphate-transport protein reconstituted in liposomes. A study on the mechanism of the inhibition. Eur. J. Biochem. 1984, 140:447-452.
58. Oliveira P.J., Wallace K.B. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology 2006, 220:160-168.
59. Goormaghtigh E., Huart P., Praet M., Brasseur R., Ruysschaert J.M. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys. Chem. 1990, 35:247-257.
60. Tao Z., Withers H.G., Penefsky H.S., Goodisman J., Souid A.K. Inhibition of cellular respiration by doxorubicin. Chem. Res. Toxicol. 2006, 19:1051-1058.
61. Souid A.K., Penefsky H.S., Sadowitz P.D., Toms B. Enhanced cellular respiration in cells exposed to doxorubicin. Mol. Pharm. 2006, 3:307-321.
62. Souid A.K., Tacka K.A., Galvan K.A., Penefsky H.S. Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochem. Pharmacol. 2003, 66:977-987.
63. Goormaghtigh E., Pollakis G., Ruysschaert J.M. Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. Biochem. Pharmacol. 1983, 32:889-893.
64. Asmis R., Wang Y., Xu L., Kisgati M., Begley J.G., Mieyal J.J. A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages. FASEB J. 2005, 19:1866-1868.
65. Sinha B.K., Mimnaugh E.G., Rajagopalan S., Myers C.E. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res. 1989, 49:3844-3848.
66. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
67. Krippner A., Matsuno-Yagi A., Gottlieb R.A., Babior B.M. Loss of function of cytochrome c in Jurkat cells undergoing fas-mediated apoptosis. J. Biol. Chem. 1996, 271:21629-21636.
68. Bossy-Wetzel E., Newmeyer D.D., Green D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 1998, 17:37-49.
69. Dey R., Moraes C.T. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J. Biol. Chem. 2000, 275:7087-7094.